ERBB2 and breast cancer: ROC curve analysis showed that the combination of age and ALBI score predicted resistance with an AUC of 0.771 (<i>95% CI: 0.642-0.900</i>), sensitivity of 72.7%, and specificity of 77.4%, demonstrating significantly superior predictive performance compared to ALBI score or age alone.<h4>Conclusion</h4>Both ALBI score and age are independent predictors influencing trastuzumab resistance in HER-2 positive BC patients.